Table 1.
Summary of efficacy and safety of the bioresorbable vascular scaffolds in clinical trials. Poly-L-lactic acid, PLLA; poly-D,L-lactic, PDLA.
| Device | Material | Year of Receiving CE Marking | Drug Eluted | Strut Thickness (µm) | Minimal Resolution Time (months) |
|---|---|---|---|---|---|
| First generation | |||||
| ABSORB | PLLA | 2012 | everolimus | 156 | >36 |
| DESolve | PLLA | 2014 | novolimus | 150 | <24 |
| DESolve Cx plus | PLLA | 2017 | novolimus | 120 | <24 |
| DREAMS 1G | Magnesium alloy | 2015 | paclitaxel | 120 | 9–12 |
| Second generation | |||||
| Magmaris (DREAMS 2G) |
Magnesium alloy | 2016 | sirolimus | 120 | 9–12 |
| Fantom | Tyrosine polycarbonate | 2017 | sirolimus | 125 | 36 |
| ART | PDLLA | 2015 | none | 170 | 6 |